Pharmacoeconomic aspects of prevention and treatment of osteoporosis

Abstract

Osteoporosis is a chronic disease with increasing prevalence and incidence, which is directly related to an aging population. Rising costs for the treatment of osteoporotic fractures and expenditure for this diagnosis is a major item of health budgets.

Pharmacoeconomic studies evaluate the cost-effectiveness of various preventive and therapeutic procedures from various perspectives (patient, payer, society).

Keywords

• osteoporosis
• pharmacoeconomics
• quality of life
• direct costs
• indirect costs
• QALY
• cost-of-illness
• Markov?s model
• cost-effectiveness
• cost-utility